{"as_of":"2026-10-15T04:50:03.855Z","query":{"query.spons":"Amgen","filter.overallStatus":"RECRUITING"},"count":20,"trials":[{"nct_id":"NCT06776250","title":"Study of How Safe and Effective Tarlatamab is in Brain Cancers","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"University Health Network, Toronto","enrollment":44,"start_date":"2025-08-18","completion_date":"2028-03-03","conditions":["Astrocytic Tumor","Oligodendroglial Tumor"],"url":"https://clinicaltrials.gov/study/NCT06776250"},{"nct_id":"NCT02009345","title":"Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada","status":"RECRUITING","phases":[],"study_type":"OBSERVATIONAL","lead_sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","enrollment":6000,"start_date":"2013-11","completion_date":"2028-11","conditions":["Familial Hypercholesterolemia","Lipid Disorder"],"url":"https://clinicaltrials.gov/study/NCT02009345"},{"nct_id":"NCT07590193","title":"A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":162,"start_date":"2026-06-11","completion_date":"2027-10-02","conditions":["Diabetes Mellitus, Type 2"],"url":"https://clinicaltrials.gov/study/NCT07590193"},{"nct_id":"NCT07614776","title":"A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":304,"start_date":"2026-05-27","completion_date":"2028-01-12","conditions":["Neovascular Age-related Macular Degeneration","nAMD"],"url":"https://clinicaltrials.gov/study/NCT07614776"},{"nct_id":"NCT06807619","title":"A Study of Sotorasib in People With Brain Tumors","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Memorial Sloan Kettering Cancer Center","enrollment":16,"start_date":"2025-01-29","completion_date":"2028-01","conditions":["Brain Tumor"],"url":"https://clinicaltrials.gov/study/NCT06807619"},{"nct_id":"NCT03315468","title":"French Clinical Datbase of Melanoma Patients (RIC-Mel)","status":"RECRUITING","phases":[],"study_type":"OBSERVATIONAL","lead_sponsor":"Nantes University Hospital","enrollment":16000,"start_date":"2012-03-01","completion_date":"2030-03-01","conditions":["Melanoma (Skin)"],"url":"https://clinicaltrials.gov/study/NCT03315468"},{"nct_id":"NCT02208869","title":"Russian Familial Hypercholesterolemia Registry","status":"RECRUITING","phases":[],"study_type":"OBSERVATIONAL","lead_sponsor":"Russian Cardiology Research and Production Center","enrollment":1000,"start_date":"2014-01","completion_date":"2026-12-31","conditions":["Familial Hypercholesterolemia"],"url":"https://clinicaltrials.gov/study/NCT02208869"},{"nct_id":"NCT05789303","title":"Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"University of Chicago","enrollment":83,"start_date":"2023-05-30","completion_date":"2028-07-01","conditions":["Multiple Myeloma","Relapse Multiple Myeloma"],"url":"https://clinicaltrials.gov/study/NCT05789303"},{"nct_id":"NCT07037758","title":"A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":380,"start_date":"2025-09-16","completion_date":"2031-01-18","conditions":["Extensive Stage Small Cell Lung Cancer"],"url":"https://clinicaltrials.gov/study/NCT07037758"},{"nct_id":"NCT03969329","title":"A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":24,"start_date":"2019-12-20","completion_date":"2027-06-30","conditions":["Secondary Hyperparathyroidism"],"url":"https://clinicaltrials.gov/study/NCT03969329"},{"nct_id":"NCT07851220","title":"A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":159,"start_date":"2026-10-01","completion_date":"2033-09-26","conditions":["Glomerulonephritis, Membranous"],"url":"https://clinicaltrials.gov/study/NCT07851220"},{"nct_id":"NCT06150781","title":"Aimovig Pregnancy Exposure Registry","status":"RECRUITING","phases":[],"study_type":"OBSERVATIONAL","lead_sponsor":"Amgen","enrollment":2842,"start_date":"2021-01-27","completion_date":"2027-10-28","conditions":["Migraine"],"url":"https://clinicaltrials.gov/study/NCT06150781"},{"nct_id":"NCT07684144","title":"Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":950,"start_date":"2026-07-29","completion_date":"2028-03-19","conditions":["Obesity","Overweight","Diabetes Mellitus, Type 2"],"url":"https://clinicaltrials.gov/study/NCT07684144"},{"nct_id":"NCT06023589","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"AstraZeneca","enrollment":231,"start_date":"2023-08-24","completion_date":"2030-08-23","conditions":["Asthma"],"url":"https://clinicaltrials.gov/study/NCT06023589"},{"nct_id":"NCT07176546","title":"TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis","status":"RECRUITING","phases":["PHASE2","PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Robert Spiera, MD","enrollment":30,"start_date":"2026-05-22","completion_date":"2030-10","conditions":["Granulomatosis With Polyangiitis","Wegener&#39;s","GPA"],"url":"https://clinicaltrials.gov/study/NCT07176546"},{"nct_id":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrollment":40,"start_date":"2025-07-02","completion_date":"2030-01-15","conditions":["Metastatic/Locally Advanced Small-Cell Lung Cancer","Metastatic/Locally Advanced Poorly Differentiated NEC"],"url":"https://clinicaltrials.gov/study/NCT07016230"},{"nct_id":"NCT07388498","title":"A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":270,"start_date":"2026-02-09","completion_date":"2028-06-18","conditions":["Uncontrolled Gout"],"url":"https://clinicaltrials.gov/study/NCT07388498"},{"nct_id":"NCT07243470","title":"Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors","status":"RECRUITING","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Centre Leon Berard","enrollment":70,"start_date":"2025-11-04","completion_date":"2030-10","conditions":["Glioma","CNS Tumor, Adult","CNS Tumor, Childhood"],"url":"https://clinicaltrials.gov/study/NCT07243470"},{"nct_id":"NCT07403721","title":"AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":464,"start_date":"2026-04-08","completion_date":"2032-02-01","conditions":["Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)"],"url":"https://clinicaltrials.gov/study/NCT07403721"},{"nct_id":"NCT06529731","title":"Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Sawa Ito, MD","enrollment":57,"start_date":"2024-09-23","completion_date":"2029-10-31","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"url":"https://clinicaltrials.gov/study/NCT06529731"}],"source":"Source: National Library of Medicine (ClinicalTrials.gov)","disclaimer":"Courtesy of the National Library of Medicine (ClinicalTrials.gov), retrieved at as_of; distributions and totals are computed by AnswerPool. Registry entries are submitted by sponsors and reflect what was registered, not verified outcomes. Not medical advice.","refresh_after":"2026-10-16T00:00:00.000Z"}